Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A.
A 5 year old boy developed severe weakness after receiving vincristine for treatment of acute lymphoblastic leukaemia. Although weakness improved after the discontinuation of vincristine, other symptoms suggestive of a neuropathy persisted. Neurophysiological and genetic analysis at age 8 years indicated that vincristine had induced symptoms of a hereditary sensory motor neuropathy type 1A, which had previously been asymptomatic; his genetically affected mother was also asymptomatic.
Mercuri
E
E
Department of Paediatrics & Neonatal Medicine, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0HN, UK. e.mercuri@ic.ac.uk
Poulton
J
J
Buck
J
J
Broadbent
V
V
Bamford
M
M
Jungbluth
H
H
Manzur
A Y
AY
Muntoni
F
F
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002607:Charcot-Marie-Tooth Disease / Q000139:chemically induced* / Q000235:genetics; D002675:Child, Preschool; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D014750:Vincristine / Q000009:adverse effects*
D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine